Patent Cliffs in the Era of Complex Therapies and Biologics

  title={Patent Cliffs in the Era of Complex Therapies and Biologics},
  author={Marco T. Sabatini and M. Silva},
  journal={Pharmaceutical Medicine},
  pages={271 - 278}
  • Marco T. Sabatini, M. Silva
  • Published 2020
  • Business, Medicine
  • Pharmaceutical Medicine
  • The rise of new product classes such as biologics and complex molecules over the past two decades have brought to light some of the unique market dynamics that such products face. While we have seen and experienced the inception, growth and expansion phase of such products, the ongoing incumbent decline due to loss of exclusivity (LoE) is yet to be fully experienced. This raises the question of how one may go about modelling such a scenario given that forecasting the expected erosion curves… CONTINUE READING

    Figures and Tables from this paper.


    The patent cliff steepens
    • 32
    The economics of biosimilars.
    • 171
    May your drug price be evergreen.
    • 13
    • PDF
    Are trade secrets delaying biosimilars?
    • 14
    Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry
    • 19
    Did the Demand for Crestor Shrink when Lipitor’s Patent Expired?
    • 1
    The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
    • 14
    Generic drug device combination products: Regulatory and scientific considerations.
    • 6
    The identity problem
    • Medicine
    • Nature Biotechnology
    • 2010
    • 4
    • PDF